Approval for the abbott axsym havab-m 2.0.  The device, as modified, will be marketed under the trade name axsym havab-m 2.0 and is indicated for the qualitative detection if igm antibody to hepatitis a virus (igm anti-hav) in human serum or plasma.  A test for igm anti-hav is indicated as an aid in the diagnosis of acute or recent hepatitis a viral infection.